Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $142.7 million.

  • Crinetics Pharmaceuticals' Operating Expenses rose 6256.71% to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.4 million, marking a year-over-year increase of 5574.19%. This contributed to the annual value of $339.9 million for FY2024, which is 4998.3% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Operating Expenses is $142.7 million, which was up 6256.71% from $130.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Operating Expenses registered a high of $142.7 million during Q3 2025, and its lowest value of $22.9 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $56.7 million (2023), whereas its average is $67.0 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 2414.45% in 2023, then surged by 6256.71% in 2025.
  • Crinetics Pharmaceuticals' Operating Expenses (Quarter) stood at $32.0 million in 2021, then soared by 50.99% to $48.3 million in 2022, then increased by 29.82% to $62.7 million in 2023, then skyrocketed by 51.21% to $94.7 million in 2024, then surged by 50.65% to $142.7 million in 2025.
  • Its Operating Expenses was $142.7 million in Q3 2025, compared to $130.1 million in Q2 2025 and $111.8 million in Q1 2025.